Zoledronic acid
- Generic Name
- Zoledronic acid
- Brand Names
- Aclasta, Reclast, Zometa, Zoledronic Acid Accord, Zoledronic acid Actavis, Zoledronic acid medac, Zoledronic acid Teva, Zoledronic Acid Hospira, Zoledronic acid Mylan
- Drug Type
- Small Molecule
- Chemical Formula
- C5H10N2O7P2
- CAS Number
- 118072-93-8
- Unique Ingredient Identifier
- 70HZ18PH24
- Background
Zoledronic acid, or CGP 42'446, is a third generation, nitrogen containing bisphosphonate similar to ibandronic acid, minodronic acid, and risedronic acid. Zoledronic acid is used to treat and prevent multiple forms of osteoporosis, hypercalcemia of malignancy, multiple myeloma, bone metastases from solid tumors, and Paget’s disease of bone. Zoledronic acid ...
- Indication
Zoledronic acid is indicated to treat hypercalcemia of malignancy, multiple myeloma, bone metastases from solid tumors, osteoporosis in men and postmenopausal women, glucocorticoid induced osteoporosis, and Paget's disease of bone in men and women. Zoledronic acid is also indicated for the prevention of osteoporosis in post menopausal women and glucocorticoi...
- Associated Conditions
- Bone Metastases, Hypercalcemia of Malignancy, Multiple Myeloma (MM), Osteoporosis, Osteoporosis caused by Glucocorticoid Treatment, Paget's Disease of Bone, Paget’s Disease
- Associated Therapies
- Bone Mineral Density
Zoledronate in Treating Patients With Cervical Intraepithelial Neoplasia 2/3 or 3
- Conditions
- Interventions
- First Posted Date
- 2006-01-18
- Last Posted Date
- 2017-11-24
- Lead Sponsor
- University of California, San Francisco
- Target Recruit Count
- 12
- Registration Number
- NCT00278434
- Locations
- 🇺🇸
UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States
Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy
- First Posted Date
- 2005-12-22
- Last Posted Date
- 2023-04-18
- Lead Sponsor
- Medical Research Council
- Target Recruit Count
- 11992
- Registration Number
- NCT00268476
- Locations
- 🇬🇧
West Suffolk Hospital, Bury St. Edmunds, England, United Kingdom
🇬🇧Derbyshire Royal Infirmary, Derby, England, United Kingdom
🇬🇧Russells Hall Hospital, Dudley, England, United Kingdom
Using TRAP to Evaluate the Effect of Zometa on Bone Metastasis Due to Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2005-12-14
- Last Posted Date
- 2018-03-05
- Lead Sponsor
- University of Louisville
- Target Recruit Count
- 28
- Registration Number
- NCT00265200
- Locations
- 🇺🇸
James Graham Brown Cancer Center, Louisville, Kentucky, United States
Safety and Efficacy Study of Concomitant Radiotherapy and Zoledronic Acid for Bone Metastases Palliation
- Conditions
- Interventions
- First Posted Date
- 2005-12-12
- Last Posted Date
- 2010-12-21
- Lead Sponsor
- The Cleveland Clinic
- Target Recruit Count
- 4
- Registration Number
- NCT00264420
Higher Frequency Zoledronic Acid in the Treatment of Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2005-12-08
- Last Posted Date
- 2011-07-21
- Lead Sponsor
- Gleneagles Hospital
- Target Recruit Count
- 56
- Registration Number
- NCT00263484
- Locations
- 🇮🇳
Christian Medical College, Vellore, Tamil Nadu, India
🇮🇳Tata Memorial Hospital, Mumbai, India
🇰🇷Chonnam National University Hwasun Hospital, Kwangju, Korea, Republic of
Adjuvant Docetaxel-Zoledronic Acid in High-risk Early Prostate Cancer Following Prostatectomy.
- First Posted Date
- 2005-11-28
- Last Posted Date
- 2010-04-26
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 1
- Registration Number
- NCT00258765
- Locations
- 🇦🇺
Novartis Investigative Site, Sydney, Australia
Paricalcitol and Zoledronate in Treating Patients With Relapsed or Refractory Multiple Myeloma or Other Plasma Cell Disorders
- Conditions
- First Posted Date
- 2005-11-24
- Last Posted Date
- 2013-02-01
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 7
- Registration Number
- NCT00258258
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
Open-label Phase IV Clinical Trial to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastases
- Conditions
- First Posted Date
- 2005-10-20
- Last Posted Date
- 2017-02-23
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 150
- Registration Number
- NCT00242554
Study of Zoledronic Acid for Patients With Hormone-sensitive Bone Metastases From Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2005-10-20
- Last Posted Date
- 2014-05-07
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 522
- Registration Number
- NCT00242567
- Locations
- 🇹🇭
Novartis Investigative Site, Songkhla, Thailand
Open-label Study, to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Bone Lesions Secondary to Multiple Myeloma.
- Conditions
- First Posted Date
- 2005-10-20
- Last Posted Date
- 2015-04-14
- Lead Sponsor
- Novartis
- Registration Number
- NCT00242528
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.